Back Pain News and Research

Latest Back Pain News and Research

PhotoMedex revenues decrease 12% to $50.1 million in first quarter 2014

PhotoMedex, Inc. reports financial results for the three months ended March 31, 2014 and announces LCA-Vision stockholder approval of PhotoMedex's previously announced acquisition of all outstanding shares of LCA-Vision, a leading provider of laser vision correction services under the LasikPlus brand.

12 May 2014

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).

6 May 2014

Teva announces positive results from pivotal Phase III study of hydrocodone bitartrate extended-release tablets

Teva Pharmaceutical Industries Ltd. today announced positive results from a pivotal Phase III study of hydrocodone bitartrate extended-release tablets designed with Teva's proprietary technology providing potential abuse-deterrent properties (CEP-33237).

30 Apr 2014

DJOFL first quarter 2014 net sales increase 1.3% to $282.7 million

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its public reporting subsidiary, DJO Finance LLC, for the first quarter ended March 29, 2014.

29 Apr 2014

Methadone safety: New clinical practice guideline from American Pain Society

Improved physician education and patient counseling about methadone safety and ECG monitoring to identify patients at high risk for cardiac problems will lead to safer use of the medication, according to the American Pain Society's Clinical Practice Guideline on Methadone Safety, published this week in The Journal of Pain.

26 Apr 2014

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.

23 Apr 2014

California Orthopaedic Medical Clinic offers comprehensive surgical solution for spinal stenosis

Like any back surgery, spinal stenosis treatment can be a significant and emotionally taxing moment in a person's life – which is why it is essential to ensure that it is effective the first time by trusting treatment to experts like Dr. Seyed M. Rezaian.

22 Apr 2014

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

21 Apr 2014

NICE recommends FIRMAGON for treating advanced hormone-dependent prostate cancer in adults with spinal metastases

The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON (degarelix) as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression.

16 Apr 2014

FzioMed receives FDA notification to convene usage of Oxiplex Gel

FzioMed, Inc., a medical device manufacturer specializing in biomaterials, has received notification from FDA that the Medical Device Dispute Resolution Panel (MDDRP) will convene and make a decision on the approvability of Oxiplex Gel on June 10, 2014.

11 Apr 2014

Study shows spinal stimulation therapy may have potential to change prognosis of people with paralysis

Four people with paraplegia are able to voluntarily move previously paralyzed muscles as a result of a novel therapy that involves electrical stimulation of the spinal cord, according to a study funded in part by the National Institutes of Health and the Christopher & Dana Reeve Foundation.

8 Apr 2014

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).

8 Apr 2014

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas Pharma Inc. and Medivation Inc. today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

4 Apr 2014

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to placebo in patients with high cholesterol.

31 Mar 2014

New ambitious Government scheme to help people return to work from sick leave

A REPORT from University of Huddersfield experts has ensured that an ambitious Government scheme to help more people return to work from sick leave will include telephone support as a key component.

29 Mar 2014

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD.

24 Mar 2014

Elsevier launches Open Access, online-only journal Internet Interventions

Elsevier, a world-leading provider of scientific, technical and medical (STM) information products and services, is pleased to announce the launch of the Open Access, online-only journal Internet Interventions.

20 Mar 2014

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

PhotoMedex, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

Study suggests surgical treatment for herniated discs increases savings to society over long term

Annually, more than 10 million people experience back pain in the United States. More than 200,000 of these patients undergo surgery to alleviate pain due to a herniated disc.

12 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

Back Pain News and Research

Latest Back Pain News and Research

PhotoMedex revenues decrease 12% to $50.1 million in first quarter 2014

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Teva announces positive results from pivotal Phase III study of hydrocodone bitartrate extended-release tablets

DJOFL first quarter 2014 net sales increase 1.3% to $282.7 million

Methadone safety: New clinical practice guideline from American Pain Society

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

California Orthopaedic Medical Clinic offers comprehensive surgical solution for spinal stenosis

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

NICE recommends FIRMAGON for treating advanced hormone-dependent prostate cancer in adults with spinal metastases

FzioMed receives FDA notification to convene usage of Oxiplex Gel

Study shows spinal stimulation therapy may have potential to change prognosis of people with paralysis

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

New ambitious Government scheme to help people return to work from sick leave

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Elsevier launches Open Access, online-only journal Internet Interventions

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

Study suggests surgical treatment for herniated discs increases savings to society over long term

Antares Pharma announces launch of OTREXUP to Dermatologists

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Back Pain News and Research

Latest Back Pain News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in